Cagrilintide
Long-acting acylated amylin analog. Once-weekly injection. Promotes satiety, slows gastric emptying. Combined with Semaglutide as CagriSema for enhanced weight loss.
Overview
Long-acting acylated amylin analog. Once-weekly injection. Promotes satiety, slows gastric emptying. Combined with Semaglutide as CagriSema for enhanced weight loss.
Significant appetite suppression, may improve fasting glucose and HbA1c (amylin reduces glucagon secretion), does not directly affect lipids or liver enzymes, GI side effects (nausea, vomiting) during titration are common
Compound Guide
Structure: Long-acting acylated analog of human amylin. Lipid modifications enable albumin binding for once-weekly dosing. Amylin is co-secreted with insulin from pancreatic beta cells.
Dosage:
- Monotherapy titration: 0.6mg/week (weeks 1-2) → 1.2mg (weeks 3-4) → 2.4mg (weeks 5-6) → 4.5mg/week (maintenance)
- CagriSema (combination): Cagrilintide + Semaglutide co-administered — up to ~20% body weight loss in clinical trials
- Bodybuilding cut: 1.2-2.4mg/week (lower doses often sufficient)
Administration:
- SubQ injection once weekly on consistent day
- Abdomen/thigh/upper arm, rotate sites
- Titrate slowly to minimise GI side effects
Key Notes:
- Amylin analog — different mechanism from GLP-1 agonists (complementary pathways)
- Promotes satiety centrally, slows gastric emptying, reduces glucagon (lowers blood sugar)
- CagriSema (Cagrilintide + Semaglutide) showed ~20% body weight loss in Phase 3 trials — more than either alone
- GI side effects (nausea, vomiting, diarrhoea) are common during titration — resolve with time
- Does not directly stimulate insulin secretion — low hypoglycaemia risk as monotherapy
- Monitor: fasting glucose, HbA1c, amylase/lipase
- Maintain high protein intake and resistance training to preserve muscle mass during weight loss
Usage History
Frequently Asked Questions
Quick Reference
Category
GLP-1
Half-Life
~7-8 days
Detection Time
N/A